Generic warfarin: Implications for patient care

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 640-643

  Wittkowsky, Ann K ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; AREA UNDER THE CURVE; BIOAVAILABILITY; BIOEQUIVALENCE; BLOOD SAMPLING; DOSE RESPONSE; DRUG SAFETY; EDITORIAL; HUMAN; PATIENT CARE;

ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DRUGS, GENERIC; HUMANS; THERAPEUTIC EQUIVALENCY; WARFARIN;

EID: 0030742078     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (7)

1. Benet LZ, Goyan JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995;15:433-40.
2. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995;108(suppl 4):231-46.
3. Patnaik R, Lesko LJ, Chan K, Williams RL. Bioequivalence of generic drugs: an American point of view. Eur J Drug Metab Pharmacokinetics 1996;21:159-64.
4. Ruedy J, Davies RO, Gagnon MA, et al. Drug bioavailability. Can Med Assoc J 1976; 115:105.
5. Wagner JG, Welling PG, Kwang PL, Walker JE. In vivo and in vitro availability of commercial warfarin tablets. J Pharm Sci 1971;60:666-77.
6. United States Pharmacopeia. Uniformity of dosage units. Rockville, MD: USP-23 Convention, Inc., 1995.
7. Richton-Hewitt S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-8.